13 nominees · 4 ballot items.
Elect thirteen directors; advisory vote to approve named executive officer compensation (Say on Pay); ratify Ernst & Young LLP as independent auditor for 2026; consider a stockholder proposal requiring shareholder approval for excessive golden parachute payments.
Elect thirteen nominated directors to the Board to serve until the next annual meeting.
Non-binding advisory vote to approve the compensation of the named executive officers for 2025 as disclosed in the proxy statement.
The proposal asks shareholders to provide a non-binding advisory approval of the Company’s 2025 named executive officer compensation as disclosed in the proxy statement. Management seeks this vote to reaffirm alignment between pay and performance, communicate responsiveness to shareholders, and maintain the Company’s practice of annual advisory votes on executive compensation. The compensation program is heavily equity-based (approximately 83% of CEO compensation and ~50% for other NEOs), uses multi-year performance shares tied to PSU Adjusted ROTCE, D+TBV/Sh and relative TSR for a portion of CEO pay, defers compensation, applies performance-based vesting and clawback provisions, and includes special awards related to the Discover acquisition. The board recommends a FOR vote, arguing the program links pay to long-term performance, balances risk, and is responsive to stockholder feedback; it cites strong 2025 company performance and governance features (clawbacks, double-trigger change-of-control, stock ownership/retention requirements) as rationale. Notable context includes the 2025 acquisition of Discover, Discover-related special awards and integration activities, and shareholder engagement that led to program adjustments such as an Executive Cash Severance Policy.
Ratify the Audit Committee’s selection of Ernst & Young LLP as the company’s independent registered public accounting firm for 2026.
A stockholder proposal asking the Board to seek shareholder approval for any NEO severance/termination payments exceeding 2.99x base salary plus target bonus, and to include the provision in Governance Guidelines.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 6.51% | 40,509,585 | $7.4B |
| 2 | STATE STREET CORP | 4.43% | 27,553,903 | $5.0B |
| 3 | Capital World Investors | 2.91% | 18,120,639 | $3.3B |
| 4 | BlackRock, Inc. | 2.63% | 16,376,920 | $3.0B |
| 5 | BlackRock, Inc. | 2.15% | 13,384,157 | $2.4B |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.97% | 12,289,260 | $2.2B |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.91% | 11,878,921 | $2.2B |
| 8 | HARRIS ASSOCIATES L P | 1.63% | 10,141,751 | $1.9B |
| 9 | DODGE COX | 1.41% | 8,774,932 | $1.6B |
| 10 | FRANKLIN RESOURCES INC | 1.39% | 8,659,737 | $1.6B |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.